These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 23347085)

  • 1. Treatment of sirolimus-eluting stent restenosis: additional stent, balloon angioplasty, and coronary artery bypass graft.
    Ishikawa K; Aoyama Y; Kato K; Tanaka A; Hiramatsu M; Ajioka M; Kamiya H; Tanaka T; Hirayama H
    J Card Surg; 2013 Mar; 28(2):97-101. PubMed ID: 23347085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of limus-eluting stents and balloon angioplasty for sirolimus-eluting in-stent restenosis.
    Ota H; Mahmoudi M; Kitabata H; Torguson R; Chen F; Satler LF; Suddath WO; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2015 Mar; 16(2):84-9. PubMed ID: 25870152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: a randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial.
    Park DW; Kim YH; Song HG; Ahn JM; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Seung KB; Yang TH; Lee SG; Lee JH; Seong IW; Cheong SS; Lee BK; Lee NH; Lee SW; Lee SW; Lee K; Kim HS; Jeon DS; Kim MK; Nah DY; Tahk SJ; Park SJ
    JACC Cardiovasc Interv; 2011 Oct; 4(10):1096-103. PubMed ID: 22017935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial.
    Hofma SH; Brouwer J; Velders MA; van't Hof AW; Smits PC; Queré M; de Vries CJ; van Boven AJ
    J Am Coll Cardiol; 2012 Jul; 60(5):381-7. PubMed ID: 22835668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
    JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
    Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
    Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial.
    King L; Byrne RA; Mehilli J; Schömig A; Kastrati A; Pache J
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):E23-8. PubMed ID: 22431239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of optimal treatment strategies for in-stent restenosis after drug-eluting stent implantation.
    Song HG; Park DW; Kim YH; Ahn JM; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Han S; Seong IW; Lee NH; Lee BK; Lee K; Lee SW; Nah DY; Park SJ
    J Am Coll Cardiol; 2012 Mar; 59(12):1093-100. PubMed ID: 22421303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.
    Holmes DR; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA;
    JACC Cardiovasc Interv; 2008 Aug; 1(4):439-48. PubMed ID: 19463342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-sirolimus-eluting stent restenosis treated with repeat percutaneous intervention: late angiographic and clinical outcomes.
    Lemos PA; van Mieghem CA; Arampatzis CA; Hoye A; Ong AT; McFadden E; Sianos G; van der Giessen WJ; de Feyter PJ; van Domburg RT; Serruys PW
    Circulation; 2004 Jun; 109(21):2500-2. PubMed ID: 15148279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors of cardiac events after implantation of sirolimus-eluting stents for treatment of in-stent restenosis.
    Le Feuvre C; Montalescot G; Rosey G; Collet JP; Beygui F; Choussat R; Gelft G; Monségu J; Ohanessian A; Spaulding C; Drobinski G; Metzger JP
    Int J Cardiol; 2006 May; 109(2):207-12. PubMed ID: 15993962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of the introduction of drug-eluting stents on the clinical practice of surgical and percutaneous treatment of coronary artery disease.
    van Domburg RT; Lemos PA; Takkenberg JJ; Liu TK; van Herwerden LA; Arampatzis CA; Smits PC; Daemen J; Venema AC; Serruys PW; Bogers AJ
    Eur Heart J; 2005 Apr; 26(7):675-81. PubMed ID: 15637087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial.
    Kufner S; Cassese S; Valeskini M; Neumann FJ; Schulz-Schüpke S; Hoppmann P; Fusaro M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA;
    JACC Cardiovasc Interv; 2015 Jun; 8(7):877-84. PubMed ID: 26003022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors of re-restenosis after repeated sirolimus-eluting stent implantation for SES restenosis and clinical outcomes after percutaneous coronary intervention for SES restenosis.
    Chatani K; Muramatsu T; Tsukahara R; Ito Y; Ishimori H; Hirano K; Nakano M; Yamawaki M; Araki M; Sakurai M; Iuchi K; Nozawa T; Inoue H
    J Interv Cardiol; 2009 Aug; 22(4):354-61. PubMed ID: 19689659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes with coronary artery bypass graft surgery versus percutaneous coronary intervention for patients with diabetes mellitus: can newer generation drug-eluting stents bridge the gap?
    Bangalore S; Toklu B; Feit F
    Circ Cardiovasc Interv; 2014 Aug; 7(4):518-25. PubMed ID: 24939927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The sirolimus-eluting Cypher Select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis: insights from the e-SELECT (Multicenter Post-Market Surveillance) registry.
    Abizaid A; Costa JR; Banning A; Bartorelli AL; Dzavik V; Ellis S; Gao R; Holmes DR; Jeong MH; Legrand V; Neumann FJ; Nyakern M; Orlick A; Spaulding C; Worthley S; Urban PM;
    JACC Cardiovasc Interv; 2012 Jan; 5(1):64-71. PubMed ID: 22230152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
    J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus-eluting stents for treatment of complex bypass graft disease: insights from the SECURE registry.
    Costa M; Angiolillo DJ; Teirstein P; Gilmore P; Leon M; Moses J; Yakubov S; Carter A; Fischell T; Zenni M; Bass T
    J Invasive Cardiol; 2005 Aug; 17(8):396-8. PubMed ID: 16079441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter).
    Rittger H; Waliszewski M; Brachmann J; Hohenforst-Schmidt W; Ohlow M; Brugger A; Thiele H; Birkemeyer R; Kurowski V; Schlundt C; Zimmermann S; Lonke S; von Cranach M; Markovic S; Daniel WG; Achenbach S; Wöhrle J
    JACC Cardiovasc Interv; 2015 Nov; 8(13):1695-700. PubMed ID: 26476609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.